Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
GLOW 70mg
70mg
Related Research News
Orforglipron Maintains Weight Loss After Stopping Injections
Results from the ATTAIN-MAINTAIN trial show that orforglipron pills helped patients keep most of their weight loss after stopping injectable tirzepatide or semaglutide. Participants switching to the daily oral GLP-1 maintained far more weight reduction than those on placebo. The study involved 376 US patients previously treated with injections for over a year.
Precision Peptide Syringes for Accurate Research Dosing
Precision syringes enable exact dosing for peptide research, featuring sterile, single-use designs with ultra-fine needles for subcutaneous injections. These tools minimize discomfort while supporting studies on compounds like BPC-157 and TB-500. Peptides, short amino acid chains, drive processes such as tissue repair and immune response in lab settings.
Lilly monthly obesity shot race with Peptron, Camurus heats up
Eli Lilly is pursuing a monthly obesity injection as South Korean biotech Peptron and Swedish Camurus compete to secure a licensing deal. The race highlights growing interest in less frequent dosing for weight loss treatments. Both companies are advancing their own long-acting formulations.